Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Endocrinol Invest ; 44(10): 2261-2271, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33656700

RESUMEN

BACKGROUND: Prader-Willi syndrome (PWS) is associated to distinctive clinical symptoms, including obesity, cognitive and behavioral disorders, and bone impairment. Irisin is a myokine that acts on several target organs including brain adipose tissue and bone. The present study was finalized to explore circulating levels of irisin in children and adult PWS patients. METHODS: Seventy-eight subjects with PWS, 26 children (15 females, mean age 9.48 ± 3.6 years) and 52 adults (30 females, mean age 30.6 ± 10.7) were enrolled. Irisin serum levels were measured in patients and controls. Its levels were related with anthropometric and metabolic parameters, cognitive performance and bone mineral density either in pediatric or adult PWS. Multiple regression analysis was also performed. RESULTS: Irisin serum levels in PWS patients did not show different compared with controls. A more in-depth analysis showed that both pediatric and adult PWS with DEL15 displayed significantly reduced irisin levels compared to controls. Otherwise, no differences in irisin concentration were found in UPD15 patients with respect to controls. Our study revealed that in pediatric PWS the 25(OH) vitamin-D levels affected irisin serum concentration. Indeed, patients who were not supplemented with vitamin D showed lower irisin levels than controls and patients performing the supplementation. Multiple regression analysis showed that irisin levels in pediatric and adult PWS were predicted by the genetic background and 25(OH)-vitamin D levels, whereas in a group of 29 adult PWS also by intelligent quotient. CONCLUSION: We demonstrated the possible role of genetic background and vitamin-D supplementation on irisin serum levels in PWS patients.


Asunto(s)
Biomarcadores/sangre , Suplementos Dietéticos , Fibronectinas/sangre , Predisposición Genética a la Enfermedad , Síndrome de Prader-Willi/tratamiento farmacológico , Vitamina D/administración & dosificación , Adulto , Estudios de Casos y Controles , Niño , Femenino , Estudios de Seguimiento , Humanos , Masculino , Síndrome de Prader-Willi/sangre , Síndrome de Prader-Willi/genética , Síndrome de Prader-Willi/patología , Pronóstico , Vitaminas/administración & dosificación
2.
J Endocrinol Invest ; 44(1): 27-35, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-32557271

RESUMEN

PURPOSE: Covid-19 is a pandemic of unprecedented proportion, whose understanding and management is still under way. In the emergency setting new or available therapies to contrast the spread of COVID-19 are urgently needed. Elderly males, especially those affected by previous diseases or with comorbidities, are more prone to develop interstitial pneumonia that can deteriorate evolving to ARDS (acute respiratory distress syndrome) that require hospitalization in Intensive Care Units (ICUs). Even children and young patients are not spared by SARS-CoV 2 infection, yet they seem to develop a milder form of disease. In this setting the immunomodulatory role of Vitamin D, should be further investigated. METHODS: We reviewed the literature about the immunomodulatory role of Vitamin D collecting data from the databases Medline and Embase. RESULTS: Vitamin D proved to interact both with the innate immune system, by activating Toll-like receptors (TLRs) or increasing the levels of cathelicidins and ß-defensins, and adaptive immune system, by reducing immunoglobulin secretion by plasma cells and pro-inflammatory cytokines production, thus modulating T cells function. Promising results have been extensively described as regards the supplementation of vitamin D in respiratory tract infections, autoimmune diseases and even pulmonary fibrosis. CONCLUSIONS: In this review, we suggest that vitamin D supplementation might play a role in the prevention and/or treatment to SARS-CoV-2 infection disease, by modulating the immune response to the virus both in the adult and pediatric population.


Asunto(s)
COVID-19/epidemiología , COVID-19/inmunología , COVID-19/terapia , Vitamina D/fisiología , Adulto , Factores de Edad , Edad de Inicio , Anciano , Anciano de 80 o más Años , COVID-19/patología , Niño , Suplementos Dietéticos , Femenino , Humanos , Inmunomodulación/efectos de los fármacos , Masculino , Pandemias , Neumonía Viral/epidemiología , Neumonía Viral/patología , Neumonía Viral/prevención & control , SARS-CoV-2/efectos de los fármacos , SARS-CoV-2/inmunología , Vitamina D/administración & dosificación , Vitamina D/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA